We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Read MoreHide Full Article
Key Takeaways
Revvity raised 2026 revenue and EPS guidance as Diagnostics organic revenues grew 11% in the second quarter.
RVTY trades at 22.9X forward earnings, above its industry, sector, S&P 500 and five-year median benchmarks.
Revvity's software revenues fell about 20%, while second-quarter free cash flow reached $183.8 million.
Revvity, Inc. (RVTY - Free Report) is entering the second half of 2026 with stronger operating momentum. Raised guidance, double-digit Diagnostics growth and better cash generation have improved the earnings setup.
The counterweight is valuation. RVTY already trades above its industry, sector and market benchmarks, while software and research-funding volatility keep execution risk in view. That mix favors a selective approach rather than treating the improving outlook as an automatic buy signal.
Revvity’s Growth Outlook Has Clearly Improved
Revvity raised 2026 pro forma revenue guidance to $2.83-$2.86 billion and adjusted earnings guidance to $5.30-$5.40 per share. The company now expects 4%-5% organic growth, up from its prior 3%-4% range.
Diagnostics is doing much of the heavy lifting. Second-quarter pro forma organic revenues rose 11%, with Reproductive Health up in the mid-teens and Immunodiagnostics outside China accelerating to the high single digits. Danaher Corporation (DHR - Free Report) also reported improving Life Sciences conditions in its second quarter, adding a useful industry read on recovering demand.
RVTY Still Trades at a Premium to Key Benchmarks
RVTY trades at 22.9X forward 12-month earnings, above the 16.5X Zacks sub-industry multiple, 21.6X sector multiple and 19.9X for the S&P 500. The stock is also above its five-year median of 21.7X.
That premium raises the bar for execution. Medpace Holdings, Inc. (MEDP - Free Report) , a global clinical contract research organization serving biotechnology and pharmaceutical customers, provides another way to track R&D spending trends, but Revvity’s own multiple already assumes investors will reward a sustained recovery.
Image Source: Zacks Investment Research
Revvity’s Software and Funding Risks Remain
Life Sciences pro forma organic revenues fell 3% in the second quarter. Software declined about 20% because of contract-renewal timing and difficult comparisons, more than offsetting low-single-digit growth in Life Sciences Solutions.
Academic and government sales also declined in the low single digits. Management expects software to return to strong double-digit growth in the second half, but uneven funding cycles and renewal timing could make that recovery less linear than the headline guidance suggests.
RVTY’s Cash Flow Supports the Portfolio Transition
Second-quarter free cash flow reached $183.8 million, equal to 117% of adjusted net income. Year-to-date free cash flow totaled $299 million, representing 108% conversion.
Revvity also retired a €500 million note in July. Management expects gross leverage to fall below 3X by year-end, while net leverage was 2.5X at quarter-end. That balance-sheet progress gives the company more flexibility as it reinvests in growth initiatives and works toward the planned China Immunodiagnostics divestiture.
RVTY’s Rank Helps, but Style Scores Urge Selectivity
The improving outlook supports the fundamental case, but valuation and mixed operating trends argue against ignoring entry price. The setup looks stronger than it did earlier in the year, yet the risk-reward remains more balanced than the raised guidance alone might imply.
RVTY currently carries a Zacks Rank #3 (Hold), while the Zacks Consensus Estimate for current-year earnings has risen 2.1% over the past four weeks. That combination points to moderately favorable near-term earnings-estimate momentum. While Medpace carries a Zacks Rank #2 (Buy), Danaher carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores are less supportive. Revvity has a Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. Because Style Scores are designed to complement the Zacks Rank, those weaker readings suggest investors may want greater selectivity despite the positive Rank, particularly while the stock trades at a premium valuation.
View the Zacks #1 Rank List
Image: Bigstock
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Key Takeaways
Revvity, Inc. (RVTY - Free Report) is entering the second half of 2026 with stronger operating momentum. Raised guidance, double-digit Diagnostics growth and better cash generation have improved the earnings setup.
The counterweight is valuation. RVTY already trades above its industry, sector and market benchmarks, while software and research-funding volatility keep execution risk in view. That mix favors a selective approach rather than treating the improving outlook as an automatic buy signal.
Revvity’s Growth Outlook Has Clearly Improved
Revvity raised 2026 pro forma revenue guidance to $2.83-$2.86 billion and adjusted earnings guidance to $5.30-$5.40 per share. The company now expects 4%-5% organic growth, up from its prior 3%-4% range.
Diagnostics is doing much of the heavy lifting. Second-quarter pro forma organic revenues rose 11%, with Reproductive Health up in the mid-teens and Immunodiagnostics outside China accelerating to the high single digits. Danaher Corporation (DHR - Free Report) also reported improving Life Sciences conditions in its second quarter, adding a useful industry read on recovering demand.
RVTY Still Trades at a Premium to Key Benchmarks
RVTY trades at 22.9X forward 12-month earnings, above the 16.5X Zacks sub-industry multiple, 21.6X sector multiple and 19.9X for the S&P 500. The stock is also above its five-year median of 21.7X.
That premium raises the bar for execution. Medpace Holdings, Inc. (MEDP - Free Report) , a global clinical contract research organization serving biotechnology and pharmaceutical customers, provides another way to track R&D spending trends, but Revvity’s own multiple already assumes investors will reward a sustained recovery.
Image Source: Zacks Investment Research
Revvity’s Software and Funding Risks Remain
Life Sciences pro forma organic revenues fell 3% in the second quarter. Software declined about 20% because of contract-renewal timing and difficult comparisons, more than offsetting low-single-digit growth in Life Sciences Solutions.
Academic and government sales also declined in the low single digits. Management expects software to return to strong double-digit growth in the second half, but uneven funding cycles and renewal timing could make that recovery less linear than the headline guidance suggests.
RVTY’s Cash Flow Supports the Portfolio Transition
Second-quarter free cash flow reached $183.8 million, equal to 117% of adjusted net income. Year-to-date free cash flow totaled $299 million, representing 108% conversion.
Revvity also retired a €500 million note in July. Management expects gross leverage to fall below 3X by year-end, while net leverage was 2.5X at quarter-end. That balance-sheet progress gives the company more flexibility as it reinvests in growth initiatives and works toward the planned China Immunodiagnostics divestiture.
Revvity Inc. Free Cash Flow (Quarterly)
Revvity Inc. free-cash-flow-quarterly | Revvity Inc. Quote
RVTY’s Rank Helps, but Style Scores Urge Selectivity
The improving outlook supports the fundamental case, but valuation and mixed operating trends argue against ignoring entry price. The setup looks stronger than it did earlier in the year, yet the risk-reward remains more balanced than the raised guidance alone might imply.
RVTY currently carries a Zacks Rank #3 (Hold), while the Zacks Consensus Estimate for current-year earnings has risen 2.1% over the past four weeks. That combination points to moderately favorable near-term earnings-estimate momentum. While Medpace carries a Zacks Rank #2 (Buy), Danaher carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores are less supportive. Revvity has a Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. Because Style Scores are designed to complement the Zacks Rank, those weaker readings suggest investors may want greater selectivity despite the positive Rank, particularly while the stock trades at a premium valuation.